Meningococcal Vaccines Market Expected to Reach USD 4.4 Billion Globally in 2022

Meningococcal Vaccines Market Expected to Reach USD 4.4 Billion Globally in 2022

  • Submitted By: Alinajohn
  • Date Submitted: 04/24/2015 2:43 AM
  • Category: Business
  • Words: 803
  • Page: 4
  • Views: 1

According to a new report published by Transparency Market Research “Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022,” the meningococcal vaccines market was valued at USD 1.5 billion in 2013 and is expected to reach a value of USD 4.4 billion in 2022, growing at a CAGR of 12.4% from 2014 to 2022.

Browse the full Meningococcal Vaccines Market Report at

Meningococcal disease is caused by the bacterium Neisseria meningitidis and occurs sporadically throughout the world with seasonal variations. It accounts for a proportion of endemic bacterial meningitis, which can progress very rapidly leading to death within 24 hours from the onset of symptoms. The disease is often misinterpreted as common flu in most of the cases. Five out of the several serogroups are known to cause meningococcal disease. The serogroups responsible for causing the disease comprise A, B, C, Y and W-135. The causative agent N. meningitidis is commonly found in the nasopharynx of humans and gets transmitted through droplet inhalation by means of close contact such as exposure to smokers, crowded living conditions such as dormitories, certain inherited disorders of the immune system, functional/anatomical asplenia or through intimate oral contact among others. According to the European Federation of Pharmaceutical Industries and Association, every year, meningitis affects almost 500,000 people globally, primarily affecting toddlers, infants and young adults, due to weaker immune system.

The global market for meningococcal vaccines is segmented broadly into vaccine types namely, polysaccharide, conjugate, combination and Men B vaccines. The report also provides analysis for vaccine under development, NmVac4-DT by JN- International that is expected to be commercialized during the forecast period 2014 to 2022. The vaccine types are further segmented by...

Similar Essays